CASTLE BIOSCIENCES INC (CSTL): Results of Operations and Financial Condition
CASTLE BIOSCIENCES INC (CSTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Castle Biosciences Reports Second Quarter 2026 Results Delivered Q2 2026 revenue of $103.5 million Q2 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 32% over Q2 2025 Raising full-year 2026 revenue guidance to
How this was made
The 30-second read
Why it matters
The key tradable items are the raised full-year revenue guidance and the company’s expectation of positive Adjusted EBITDA starting in Q3 2026, alongside reported growth in core test volumes and margin metrics.
Market read
Q2 results show accelerating core test report growth and the company upgrades 2026 revenue guidance while targeting positive Adjusted EBITDA beginning in Q3.
What to watch
Revenue comparisons are affected by Medicare coverage changes and discontinuation of IDgenetix, so traders may want to separate underlying demand growth from coverage-driven effects.
Background
The article is Castle Biosciences’ SEC Form 8-K reporting Q2 2026 results and providing updated 2026 outlook, plus recent accomplishments in dermatology and skin cancer testing.
Ticker impact
Castle Biosciences raised 2026 revenue guidance to $365-375 million and expects positive Adjusted EBITDA in Q3, Q4, and full-year 2026.
Likely positive bias for the next few sessions as traders price in higher 2026 revenue and the stated path to positive Adjusted EBITDA.
The filing is a primary disclosure (8-K with results) and includes explicit numerical guidance and a profitability timing statement, both of which are direct inputs to valuation and positioning.
Market effects
Supports sentiment for oncology and dermatology diagnostics names by highlighting growth in core test volumes and improving margins.
Limited, primarily impacts US small/mid-cap biotech and diagnostics sentiment.
Low, largely company-specific guidance and clinical/assay updates.
Counterpoint
Despite the guidance raise, gross margin and cash from operations were mixed versus prior periods, and Adjusted EBITDA improvement may still be sensitive to reimbursement and commercial execution.
Key entities
- issuerCastle Biosciences, Inc.
Nasdaq-listed diagnostics company reporting Q2 2026 results and raising 2026 revenue guidance.
- productDecisionDx-Melanoma
Core test driver with reported Q2 and six-month test report growth.
- productTissueCypher
Core test driver with reported Q2 and six-month test report growth.
- productAdvanceAD-Tx
Atopic dermatitis test referenced for clinical impact and NYSDOH assay approval.
